Karyopharm Therapeutics Inc Cash Flow Conversion Efficiency
Karyopharm Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has a cash flow conversion efficiency ratio of 0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.93 Million) by net assets ($-330.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Karyopharm Therapeutics Inc (2011–2025)
Cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025. This chart illustrates how Karyopharm Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View KPTI live share price for real-time trading data and today's change.
Karyopharm Therapeutics Inc Cash Flow Conversion Ratio Explained
Karyopharm Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Karyopharm Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Karyopharm Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Desert Mountain Energy Corp
V:DME
|
-0.006x |
|
Pixelplus. Co. Ltd
KQ:087600
|
-0.002x |
|
Clime Investment Management Ltd
AU:CIW
|
-0.055x |
|
Société Hôtelière et Immobilière de Nice S.A.
PA:MLHIN
|
N/A |
|
Wooyang Co. Ltd
KQ:103840
|
0.087x |
|
Made SA
PA:MLMAD
|
N/A |
|
The Western India Plywoods Limited
NSE:WIPL
|
0.093x |
|
Tips Films Limited
NSE:TIPSFILMS
|
0.372x |
Annual Cash Flow Conversion Efficiency for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025. Review how much free cash does Karyopharm Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-292.93 Million | $-75.37 Million | 0.257x | -62.46% |
| 2024-12-31 | $-186.02 Million | $-127.49 Million | 0.685x | +0.67% |
| 2023-12-31 | $-136.21 Million | $-92.72 Million | 0.681x | -92.42% |
| 2022-12-31 | $-16.66 Million | $-149.55 Million | 8.979x | +567.86% |
| 2021-12-31 | $-79.67 Million | $-107.12 Million | 1.344x | +142.41% |
| 2020-12-31 | $50.55 Million | $-160.23 Million | -3.170x | +17.31% |
| 2019-12-31 | $49.77 Million | $-190.82 Million | -3.834x | -341.33% |
| 2018-12-31 | $183.17 Million | $-159.12 Million | -0.869x | -52.56% |
| 2017-12-31 | $129.46 Million | $-73.72 Million | -0.569x | -9.47% |
| 2016-12-31 | $162.24 Million | $-84.39 Million | -0.520x | -9.73% |
| 2015-12-31 | $198.37 Million | $-94.03 Million | -0.474x | -90.53% |
| 2014-12-31 | $206.79 Million | $-51.45 Million | -0.249x | -27.25% |
| 2013-12-31 | $154.93 Million | $-30.29 Million | -0.196x | -135.14% |
| 2012-12-31 | $-27.88 Million | $-15.51 Million | 0.556x | -17.67% |
| 2011-12-31 | $-12.65 Million | $-8.55 Million | 0.676x | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more